Oligodeoxynucleotides containing CpG motifs induce low levels of TNF-α in human B lymphocytes:: Possible adjuvants for Th1 responses

被引:23
作者
Bohle, B [1 ]
Orel, L [1 ]
Kraft, D [1 ]
Ebner, C [1 ]
机构
[1] Univ Vienna, Dept Pathophysiol, Div Immunopathol, A-1090 Vienna, Austria
关键词
D O I
10.4049/jimmunol.166.6.3743
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Oligodeoxynucleotides containing CpG motifs (CpG-ODN) represent potential adjuvants for specific immunotherapy of type I allergies because they foster Th1-like immune responses. However, previous work has shown that CpG-ODN induce systemically active levels of TNF-alpha in murine macrophages. The goal of the present study was to evaluate the release of TNF-alpha in human cells by a CpG-ODN proven to induce Th1 immune responses in cells from atopic individuals and in mice. CpG-ODN induced TNF-alpha in cells from atopic and healthy individuals. However, the amounts were low, as determined by comparison with commonly used Ags, Intracellular cytokine staining of PBMC revealed that CpG-ODN-induced TNF-alpha derived exclusively from B lymphocytes. TNF-cu contributed to the CpG-ODN-augmented proliferation and Tg synthesis in PBMC, but was not involved in IFN-gamma synthesis. In conclusion, our findings indicate that certain CpG-ODN induce low amounts of TNF-alpha in human B lymphocytes and may therefore be used to modulate Th2-biased immune responses in allergic patients.
引用
收藏
页码:3743 / 3748
页数:6
相关论文
共 36 条
[1]   DNA activates human immune cells through a CpG sequence-dependent manner [J].
Bauer, M ;
Heeg, K ;
Wagner, H ;
Lipford, GB .
IMMUNOLOGY, 1999, 97 (04) :699-705
[2]  
Bohle B, 1998, J IMMUNOL, V160, P2022
[3]   Characterization of T cell responses to Hev b 3, an allergen associated with latex allergy in spina bifida patients [J].
Bohle, B ;
Wagner, B ;
Vollmann, U ;
Buck, D ;
Niggemann, B ;
Szépfalusi, Z ;
Fischer, G ;
Scheiner, O ;
Breiteneder, H ;
Ebner, C .
JOURNAL OF IMMUNOLOGY, 2000, 164 (08) :4393-4398
[4]  
Bohle B, 1999, EUR J IMMUNOL, V29, P2344, DOI 10.1002/(SICI)1521-4141(199907)29:07<2344::AID-IMMU2344>3.0.CO
[5]  
2-R
[6]   Allergen immunotherapy: Therapeutic vaccines for allergic diseases - A WHO position paper [J].
Bousquet, J ;
Lockey, R ;
Malling, HJ .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1998, 102 (04) :558-562
[7]  
Broide D, 1998, J IMMUNOL, V161, P7054
[8]   CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity [J].
Chu, RS ;
Targoni, OS ;
Krieg, AM ;
Lehmann, PV ;
Harding, CV .
JOURNAL OF EXPERIMENTAL MEDICINE, 1997, 186 (10) :1623-1631
[9]   CpG DNA overcomes hyporesponsiveness to hepatitis B vaccine in orangutans [J].
Davis, HL ;
Suparto, I ;
Weeratna, R ;
Jumintarto ;
Iskandriati, D ;
Chamzah, S ;
Ma'ruf, A ;
Nente, C ;
Pawitri, D ;
Krieg, AM ;
Heriyanto ;
Smits, W ;
Sajuthi, D .
VACCINE, 2000, 18 (18) :1920-1924
[10]   Immunostimulatory CpG-oligonucleotides cause proliferation, cytokine production, and an immunogenic phenotype in chronic lymphocytic leukemia B cells [J].
Decker, T ;
Schneller, F ;
Sparwasser, T ;
Tretter, T ;
Lipford, GB ;
Wagner, H ;
Peschel, C .
BLOOD, 2000, 95 (03) :999-1006